褪黑素
基因敲除
癌症研究
下调和上调
细胞凋亡
癌基因
细胞生长
肺癌
生物
转移
组蛋白脱乙酰基酶
体内
细胞周期
医学
内科学
癌症
组蛋白
基因
生物技术
生物化学
遗传学
作者
Zhiqiang Ma,Dong Liu,Shouyin Di,Zhipei Zhang,Weimiao Li,Jiao Zhang,Liqun Xu,Kai Xia Guo,Yifang Zhu,Xiaofei Li,Jing Yi Han,Xiaolong Yan
摘要
Histone deacetylase 9 functions as an oncogene in a variety of cancers, but its role on non-small cell lung cancer (NSCLC) has not been reported. Melatonin was proven to possess anticancer actions, whereas its effect on NSCLC and underlying mechanisms remains poorly understood. In this study, 337 patients with complete clinicopathologic characteristics who underwent NSCLC surgery were recruited for the study. We found that NSCLC patients with high HDAC9 expression were correlated with worse overall survival and poor prognosis. HDAC9 knockdown significantly reduced NSCLC cell growth and induced apoptosis both in vivo and in vitro. Melatonin application also markedly inhibited cell proliferation, metastasis, and invasion and promoted apoptosis in NSCLC cells. Moreover, RNA-seq, real-time quantitative polymerase chain reaction, and western blot analyses showed that melatonin treatment decreased the HDAC9 level in NSCLC cells. A mechanistic study revealed that HDAC9 knockdown further enhanced the anticancer activities of melatonin treatment, whereas HDAC9 overexpression partially reversed the melatonin's anticancer effects. Additionally, the in vivo study found melatonin exerted anti-proliferative and pro-apoptotic effects on xenograft tumors which were also strengthened by HDAC9 knockdown. These results indicated that HDAC9 downregulation mediated the anti-NSCLC actions of melatonin, and targeting HDAC9 may be the novel therapeutic strategy for NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI